Major Depressive Disorder (MDD): Clinical Symptoms, Neurotransmitters, and Therapy
The major depressive disorder (MDD) is a debilitating neuropsychiatric condition involving persistent depressive symptoms, anhedonia and cognitive-affective dysfunction. This essay will explore the current neurobiological mechanisms involved in MDD such as neuroinflammation, HPA axis dysfunction, synaptic atrophy due to BDNF, and evidence based psychological therapy.
Hands-free audio narration
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
The major depressive disorder (MDD) is a debilitating neuropsychiatric condition involving persistent depressive symptoms, anhedonia and cognitive-affective dysfunction. This essay will explore the current neurobiological mechanisms involved in MDD such as neuroinflammation, HPA axis dysfunction, synaptic atrophy due to BDNF, and evidence based psychological therapy.
Major Depressive Disorder (MDD) is now understood in modern psychiatry and clinical neuroscience to be a complex multi-system biological illness, not a personal failing or short-term sadness. For many years it was overly simplified to a "chemical imbalance" in the brain with low levels of serotonin.
Modern research has shown that depression results in widespread impairments in neuroplasticity, neural connectivity and neuroinflammation. Prolonged allostatic stress causes abnormally high levels of glutamate excitotoxicity and increased levels of glucocorticoids. This causes a decrease in Brain-Derived Neurotropic Factor (BDNF), and subsequent dendritic spine atrophy in the hippocampus and prefrontal cortex. The amygdala is also hyperactive.
Full remission can only be achieved by utilising a multi-modal approach using neuroplasticity enhancing drugs in conjunction with psychotherapy and anti-inflammatory lifestyle measures.
Neurobiology: Synaptic Plasticity, BDNF, & Neural Circuits
Pharmacological Classes for Major Depressive Disorder
| Medication Class | Key Medications | Mechanism of Action | Clinical Considerations & Side Effects |
|---|---|---|---|
| Selective Serotonin Reuptake Inhibitors (SSRIs) | Escitalopram (Lexapro), Sertraline (Zoloft), Fluoxetine | Selectively blocks SERT reuptake transporter, increasing synaptic serotonin concentration. | First-line gold standard; favorable safety profile. Monitor for transient nausea, sexual dysfunction, or insomnia. |
| Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) | Duloxetine (Cymbalta), Venlafaxine (Effexor) | Inhibits reuptake of both serotonin and norepinephrine. | Excellent for depression co-occurring with chronic neuropathic pain, fibromyalgia, or fatigue. |
| Atypical Antidepressants | Bupropion (Wellbutrin), Mirtazapine (Remeron) | Inhibits Dopamine/Norepinephrine reuptake (Bupropion); Alpha-2 antagonist (Mirtazapine). | Bupropion has zero sexual side effects and aids smoking cessation; Mirtazapine promotes sleep and appetite. |
| NMDA Receptor Antagonists | Esketamine (Spravato nasal spray), IV Ketamine | Non-competitive NMDA glutamate receptor antagonist triggering rapid mTOR-mediated synaptogenesis. | Rapid anti-depressant and anti-suicidal efficacy within hours; FDA-approved for Treatment-Resistant Depression. |
| Neuromodulation Therapies | Transcranial Magnetic Stimulation (TMS), Electroconvulsive Therapy (ECT) | Magnetic pulses (TMS) or controlled seizure induction (ECT) targeting prefrontal cortex. | Non-pharmacological gold standard for severe treatment-resistant or psychotic depression. |
DSM-5 Diagnostic Criteria Checklist (SIGECAPS Mnemonic)
Neurotrophic Hypothesis, The DSM-5-TR Diagnostic Criteria & The STAR*D Trial
First-Line SSRI/SNRI Selection, Bupropion Mechanisms & Breakthrough Esketamine
Frequently Asked Questions
Dr. Randeep Guleria, MBBS, MD, DM
Chairman, Internal Medicine & Respiratory Sciences, Medanta (Former Director, AIIMS New Delhi) • MBBS, MD, DM (Pulmonary Medicine & Critical Care)Dr. Randeep Guleria is the Chairman of the Institute of Internal Medicine, Respiratory & Sleep Medicine at Medanta – The Medicity and former Director of AIIMS New Delhi. A Padma Shri awardee and one of India's most respected medical authorities, he oversees preventive healthcare, vaccination literacy, and clinical safety standards at mediguide4u.
References & Clinical Resources
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (2010). [Access Resource Link] — 3rd Edition. APA Guidelines
- Malhi GS, Mann JJ. Neurobiology of Depression: An Integrated View of Key Findings (2018). [Access Resource Link] — The Lancet. 392(10161):2299-2312
- Daly EJ, Trivedi MH, Janik A, et al.. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression (SUSTAIN-1) (2019). [Access Resource Link] — JAMA Psychiatry. 76(9):893-903
Related Healthcare Guides
The Science of Stress Management: Neurobiology, Cortisol Regulation, and Clinical Techniques
Obstructive Sleep Apnea (OSA): STOP-Bang Screening, CPAP Therapy, and Heart Health
Migraine vs. Tension Headache: Aura, CGRP Pathway, Triggers, and Abortive Treatments
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
The neurobiological breakdown of the HPA axis, cortisol dysregulation, and amygdala reactivity helped me understand that chronic burnout is a physiological condition, not a personal failing.
Understanding the biological basis of chronic autonomic nervous system stress helps dismantle shame and guides effective, restorative recovery protocols, Jonathan.
Clear, compassionate, and scientifically rigorous. The comparison between cognitive behavioral exposure therapy and pharmacotherapy provides great balanced guidance for my clients.
Thank you, Megan. Presenting both psychotherapy and evidence-based medical treatments neutrally allows individuals to make informed collaborative decisions with their providers.